Multiple myeloma therapy, ‘Kyprolis’ conducted Phase 3 clinical trials on Koreans
The new multiple myeloma therapy, ‘Kyprolis(carfilzomib, Amgen),’ will start a Phase 3 clinical trial adding 16 Korean subjects.
It has attracted interests of the industry since it is a newly-approved clinical trial targeting Koreans in the circumstance where the insurance benefit is about to be...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
